United States Department of Justice 

Drug Enforcement Administration 

Office of Diversion Control 

Practitioner’s Manual 

An Informational Outline of the 

Controlled Substances Act

2006 Edition 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

ii 

Joseph T. Rannazzisi 

Deputy Assistant Administrator 

Office of Diversion Control 

Mark W. Caverly 

Chief, Liaison and Policy Section 

This manual has been prepared by the Drug Enforcement Administration, Office of 

Diversion Control, to assist practitioners (physicians, dentists, veterinarians, and other 

registrants authorized to prescribe, dispense, and administer controlled substances) in their 

understanding of the Federal Controlled Substances Act and its implementing regulations as 

they pertain to the practitioner’s profession. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

iii 

Table of Contents 

Section I - Introduction 

Disclaimer...................................................................................... 1 

Authorization for Public Dissemination................................................... 2 

Message from the Administrator........................................................... 3 

Preface.......................................................................................... 4 

Section II – General Requirements 

Schedules of Controlled Substances........................................................ 5 

Schedule I Substances ............................................................... 5 

 Schedule II Substances............................................................... 5 

 Schedule III Substances............................................................. 6 

 Schedule IV Substances............................................................ 6 

 Schedule V Substances.............................................................. 6 

Registration Requirements.................................................................. 7 

 Application for Registration...................................................... 7 

 Certificate of Registration......................................................... 8 

 Registration Renewals............................................................ 9 

Change of Business Address................................................................. 11 

Termination of Registration............................................................... 11 

Denial, Suspension or Revocation of Registration....................................... 11 

Practitioner’s Use of a Hospital’s DEA Registration Number......................... 12 

Inappropriate Use of the DEA Registration Number.................................... 12 

Exemption of Federal Government Practitioners from Registration................... 13 

Section III – Security Requirements 

Required Controls............................................................................. 14

Safeguards for Prescribers................................................................... 15 

Section IV – Recordkeeping Requirements 

Recordkeeping Requirements............................................................... 16 

 Inventory.............................................................................. 16 

 Disposal of Controlled Substances................................................ 17 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

iv 

Table of Contents (continued) 

Section V – Valid Prescription Requirements 

Prescription Requirements................................................................... 18 

Who May Issue....................................................................... 18 

Purpose of Issue...................................................................... 19 

Schedule II Substances....................................................................... 19 

 Refills................................................................................. 19 

 Issuance of Multiple Prescriptions for Schedule II Substances................ 19 

 Facsimile Prescriptions for Schedule II Substances............................. 20 

 Exceptions for Schedule II Facsimile Prescriptions............................. 21 

Schedule III-V Substances.................................................................. 21 

Refills................................................................................. 21 

 Facsimile Prescriptions for Schedule III-V Substances........................ 22 

 Telephone Authorization for Schedule III-V Prescriptions.................... 22

Delivery of a Controlled Substance to Persons Outside the U.S....................... 22 

 

Section VI – Opioid (Narcotic) Addiction Treatment Programs 

Opioid (Narcotic) Addiction Treatment Programs........................................23 

Appendices 

Appendix A CSA and CFR Definitions................................................. 26 

Appendix B Questions and Answers.................................................... 28 

Appendix C Summary of Controlled Substances Act Requirements................ 32 

Appendix D Internet Resources........................................................... 33 

Appendix E DEA Diversion Field Office Locations...................................34 

Appendix F Small Business and Agriculture Regulatory Enforcement 

 Ombudsman................................................................. 40 

Appendix G Additional Assistance and Plain Language Statements................ 41 

Appendix H DEA Forms.................................................................. 42 

DEA Form 41 - Registrants Inventory of Drugs Surrendered................. 43

 DEA Form 106 – Report of Theft or Loss of Controlled Substances......... 45 

DEA Form 222 - U.S. Official Order Form for Controlled Substances...... 47

 DEA Form 224 – Application for Registration...................................48

 DEA Form 224a - Renewal Application for Registration...................... 52 

 DEA Form 363 - Application for Registration Under the Narcotic 

 Addict Treatment Act of 1974............................................ 56 

 DEA Form 363a – Renewal for Registration Under the Narcotic 

 Addict Treatment Act of 1974......................................... 60 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 1 

SECTION I - INTRODUCTION 

This practitioner’s manual is intended to summarize and explain the basic requirements for 

prescribing, administering, and dispensing controlled substances under the Controlled 

Substances Act (CSA), 21 USC 801-890, and the DEA regulations, Title 21, Code of Federal 

Regulations (CFR), Parts 1300 to 1316. Pertinent citations to the law and regulations are 

included in this manual. 

Printed copies of the CFR and the complete regulations implementing the CSA may be 

obtained from: 

Superintendent of Documents 

U.S. Government Printing Office 

Washington, D.C. 20402 

Both the CFR and the Federal Register (which includes proposed and final regulations 

implementing the CSA) are available on the Internet through the U.S. Government Printing 

Office (GPO) website. This website, which provides information by section, citation and 

keywords, can be accessed at: 

www.gpoaccess.gov/cfr/index.html

Unofficial copies of pertinent CFR citations may be found at: 

www.DEAdiversion.usdoj.gov

This practitioner’s manual may also be found on the Internet at DEA’s Web Site (under 

“publications”): 

www.DEAdiversion.usdoj.gov

Should any pertinent provisions of the law or regulations be modified in the future, DEA will 

issue a revised electronic version of this document, which will be published on the DEA 

Diversion Website. 

If you encounter errors in this document, please notify: 

 Editor, DEA Practitioner’s Manual 

 c/o DEA, Office of Diversion Control 

 Liaison and Policy Section 

 Washington, D.C. 20537 

Inquiries regarding topics within this document may be addressed to your local DEA field 

office (listed in Appendix E) or the address above. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 2 

This Document is Authorized for Public Dissemination 

All material in this publication is in the public domain and may be reproduced without the 

express permission of the Drug Enforcement Administration. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 3 

Message from the Administrator 

The Drug Enforcement Administration is pleased to provide this updated edition of the 1990 

Practitioner’s Manual to assist you in understanding your responsibilities under the 

Controlled Substances Act (CSA) and its implementing regulations. This manual will help 

answer questions that you may encounter in your practice and provide guidance in complying 

with federal requirements. 

DEA remains committed to the 2001 Balanced Policy of promoting pain relief and 

preventing abuse of pain medications. In enforcing the CSA, it is DEA’s responsibility to 

ensure drugs are not diverted for illicit purposes. Unfortunately, this country is now 

experiencing an alarming prescription drug abuse problem: 

• Today, more than 6 million Americans are abusing prescription drugs—that is more 

than the number of Americans abusing cocaine, heroin, hallucinogens, and inhalants, 

combined. 

• Researchers from the Centers for Disease Control and Prevention report that opioid 

prescription painkillers now cause more drug overdose deaths than cocaine and 

heroin combined. 

• Today more new drug users have begun abusing pain relievers (2.4 million) than 

marijuana (2.1 million) or cocaine (1.0 million). 

It is more important now than ever to be vigilant in preventing the diversion and abuse of 

controlled substances. This manual will help you do that by listing some safeguards you can 

take to prevent such diversion. It also explains registration, recordkeeping, and valid 

prescription requirements. 

As a practitioner, your role in the proper prescribing, administering, and dispensing of 

controlled substances is critical to patients’ health and to safeguarding society against the 

diversion of controlled substances. DEA is committed to working jointly with the medical 

community to ensure that those in need are cared for and that legitimate controlled 

substances are not being diverted for illegal use. 

Karen P. Tandy 

Administrator 

September 2006 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 4 

Preface 

The Drug Enforcement Administration (DEA) was established in 1973 to serve as the 

primary federal agency responsible for the enforcement of the Controlled Substances Act 

(CSA). The CSA sets forth the federal law regarding both illicit and licit (pharmaceutical) 

controlled substances. With respect to pharmaceutical controlled substances, DEA’s 

statutory responsibility is twofold: to prevent diversion and abuse of these drugs while 

ensuring an adequate and uninterrupted supply is available to meet the country’s legitimate 

medical, scientific, and research needs. In carrying out this mission, DEA works in close 

cooperation with state and local authorities and other federal agencies. 

Under the framework of the CSA, the DEA is responsible for ensuring that all controlled 

substance transactions take place within the “closed system” of distribution established by 

Congress. Under this “closed system,” all legitimate handlers of controlled substances – 

manufacturers, distributors, physicians, pharmacies, and researchers – must be registered 

with DEA and maintain strict accounting for all distributions. 

To carry out DEA’s mission effectively, this 2006 Practitioner’s Manual seeks to aid DEA 

registrants in complying with the CSA and its implementing regulations. The DEA 

understands that it can best serve the public interest by working with practitioners to prevent 

diversion of legal pharmaceutical controlled substances into the illicit market. 

The federal controlled substances laws are designed to work in tandem with state controlled 

substance laws. Toward this same goal, DEA works in close cooperation with state 

professional licensing boards and state and local law enforcement officials to ensure that 

pharmaceutical controlled substances are prescribed, administered, and dispensed for 

legitimate medical purposes in accordance with federal and state laws. Within this 

cooperative framework, the majority of investigations into possible violations of the 

controlled substances laws are carried out by state authorities. However, DEA also conducts 

investigations into possible violations of federal law as circumstances warrant. 

In the event a state board revokes the license of a practitioner, the DEA will take action and 

request a voluntary surrender of the practitioner’s DEA registration. If the practitioner 

refuses to voluntarily surrender the registration, the DEA will pursue administrative action to 

revoke the DEA registration. The DEA may also pursue judicial action if there is sufficient 

evidence of illegal distribution or significant recordkeeping violations. All such actions are 

intended to deny the practitioner the means to continue to divert or abuse controlled 

substances as well as to protect the health and safety of the public and the practitioner. 

The DEA is authorized under federal law to pursue legal action in order to prevent the 

diversion of controlled substances and protect the public safety. A lack of compliance may 

result in a need for corrective action, such as administrative action (that is, Letter of 

Admonition, an informal hearing or “order to show cause”), or in extreme cases, civil, or 

criminal action. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 5 

SECTION II – GENERAL REQUIREMENTS 

Schedules of Controlled Substances 

The drugs and other substances that are considered controlled substances under the CSA are 

divided into five schedules. A complete list of the schedules is published annually on an 

updated basis in the DEA regulations, Title 21 of the Code of Federal Regulations, Sections 

1308.11 through 1308.15. Substances are placed in their respective schedules based on 

whether they have a currently accepted medical use in treatment in the United States and 

their relative abuse potential and likelihood of causing dependence when abused. Some 

examples of the drugs in each schedule are outlined below. 

IMPORTANT NOTE: 

All drugs listed in Schedule I have no currently accepted medical use in treatment in the 

United States and therefore may not be prescribed, administered, or dispensed for medical 

use. In contrast, drugs listed in Schedules II through V all have some accepted medical use 

and therefore may be prescribed, administered, or dispensed for medical use. 

 Schedule I Substances 

Substances in this schedule have no currently accepted medical use in treatment in the 

United States, a lack of accepted safety for use under medical supervision, and a high 

potential for abuse. 

Some examples of substances listed in Schedule I are: heroin; lysergic acid diethylamide 

(LSD); marijuana (cannabis); peyote; methaqualone; and methylene-dimethoxymethamphetamine (“ecstasy”). 

The CSA allows for bona fide research with controlled substances in Schedule I, 

provided that the FDA has determined the researcher to be qualified and competent, and 

provided further that the FDA has determined the research protocol to be meritorious. 

Researchers who meet these criteria must obtain a separate registration to conduct 

research with a Schedule I controlled substance. 

 Schedule II Substances 

Substances in this schedule have a high potential for abuse with severe psychological or 

physical dependence. 

 

Examples of single entity Schedule II narcotics include morphine, codeine, and opium. 

Other Schedule II narcotic substances and their common name brand products include: 

hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), 

oxycodone (OxyContin®), and fentanyl (Sublimaze® or Duragesic®). 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 6 

Examples of Schedule II stimulants include amphetamine (Dexedrine® or Adderall®), 

methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II 

substances include: cocaine, amobarbital, glutethimide, and pentobarbital. 

 Schedule III Substances 

Substances in this schedule have a potential for abuse less than substances in Schedules I 

or II.

Examples of Schedule III narcotics include combination products containing less than 15 

milligrams of hydrocodone per dosage unit (i.e., Vicodin®) and products containing not 

more than 90 milligrams of codeine per dosage unit (i.e., Tylenol with codeine®). 

Examples of Schedule III non-narcotics include benzphetamine (Didrex®), 

phendimetrazine, dronabinol (Marinol®), ketamine, and anabolic steroids such as 

oxandrolone (Oxandrin®). 

 Schedule IV Substances 

 Substances in this schedule have a lower potential for abuse relative to substances in 

 Schedule III.

 Examples of a Schedule IV narcotics include propoxyphene (Darvon® and 

 Darvocet-N 100®). 

 Other Schedule IV substances include alprazolam (Xanax®), clonazepam (Klonopin®), 

 clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam 

 (Versed®), temazepam (Restoril®), and triazolam (Halcion®). 

Schedule V Substances 

Substances in this schedule have a lower potential for abuse relative to substances listed 

in Schedule IV and consist primarily of preparations containing limited quantities of 

certain narcotic and stimulant drugs. These are generally used for antitussive, 

antidiarrheal and analgesic purposes. 

Examples include cough preparations containing not more than 200 milligrams of 

codeine per 100 milliliters or per 100 grams (Robitussin AC®, and Phenergan with 

Codeine®). 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 7 

Registration Requirements 

Under the CSA, the term “practitioner” is defined as a physician, dentist, veterinarian, 

scientific investigator, pharmacy, hospital, or other person licensed, registered, or otherwise 

permitted, by the United States or the jurisdiction in which the practitioner practices or 

performs research, to distribute, dispense, conduct research with respect to, administer, or use 

in teaching or chemical analysis, a controlled substance in the course of professional practice 

or research. Every person or entity that handles controlled substances must be registered 

with DEA or be exempt by regulation from registration. 

The DEA registration grants practitioners federal authority to handle controlled substances. 

However, the DEA registered practitioner may only engage in those activities that are 

authorized under state law for the jurisdiction in which the practice is located. When federal 

law or regulations differ from state law or regulations, the practitioner is required to abide by 

the more stringent aspects of both the federal and state requirements. In many cases, state 

law is more stringent than federal law, and must be complied with in addition to federal law. 

Practitioners should be certain they understand their state as well as DEA controlled 

substance regulations. 

Application for Registration 

To obtain a DEA registration, a practitioner must apply using a DEA Form 224. 

Applicants may submit the form by hard copy or on-line. Complete instructions 

accompany the form. To obtain the application, DEA may be contacted at: 

• www.DEAdiversion.usdoj.gov (DEA Diversion Internet Web Site) 

• any DEA field office (see listing in Appendix E of this manual) 

• DEA Headquarters’ Registration Section in Washington, D.C. at 1-800-882-9539 

(Registration Call Center) 

 The DEA Form-224 may be completed on-line or in hard copy and mailed to: 

Drug Enforcement Administration 

Registration Unit 

Central Station 

P.O. Box 28083 

Washington, D.C. 20038-8083 

A sample DEA Form 224 – New Application for Registration, is located at Appendix H, 

DEA Forms. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 8 

Certificate of Registration 

The DEA Certificate of Registration (DEA Form 223) must be maintained at the 

registered location in a readily retrievable manner and kept available for official 

inspection. 

The CSA requires that a separate registration be obtained for each principal place of 

business or professional practice where controlled substances are manufactured, 

distributed, or dispensed. DEA has historically provided an exception that a practitioner 

who is registered at one location, but also practices at other locations, is not required to 

register separately for any other location at which controlled substances are only 

prescribed. If the practitioner maintains supplies of controlled substances, administers, 

or directly dispenses controlled substances at the separate location the practitioner must 

obtain a separate DEA registration for that location. The exception applies only to a 

secondary location within the same state in which the practitioner maintains his/her 

registration. DEA individual practitioner registrations are based on state authority to 

dispense or conduct research with respect to controlled substances. Since a DEA 

registration is based on a state license, it cannot authorize controlled substance 

dispensing outside that state. Hence, the separate registration exception applies only to 

locations within the same state in which practitioners have their DEA registrations. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 9 

A duplicate Certificate of Registration may be requested on-line. It appears on DEA’s 

website, www.DEAdiversion.usdoj.gov, as follows: 

Registration Renewals 

Practitioner registrations must be renewed every three years. Renewal registrations use 

DEA Form 224a, Renewal Application for DEA Registration (see example at Appendix 

H, DEA Forms). The cost of the registration is indicated on the application form. 

A renewal application is sent to the registrant approximately 45 days before the 

registration expiration date. The renewal application is sent to the address listed on the 

current registration certificate. If the renewal form is not received within 30 days before 

the expiration date of the current registration, the practitioner should contact the DEA 

registration office for their state, or DEA Headquarters at 1-800-882-9539, and request a 

renewal registration form. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 10 

The registration renewal application may be completed on-line at 

www.DEAdiversion.usdoj.gov, or in hard copy and mailed to: 

Drug Enforcement Administration 

Registration Unit 

Central Station 

P.O. Box 28083 

Washington, D.C. 20038-8083 

 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 11 

Change of Business Address 

A practitioner who moves to a new physical location must request a modification of 

registration. A modification of registration can be requested on-line at 

www.DEAdiversion.usdoj.gov or in writing to the DEA field office responsible for that state. 

If the change in address involves a change in state, the proper state issued license and 

controlled substances registration must be obtained prior to the approval of modification of 

the federal registration. If the modification is approved, DEA will issue a new certificate of 

registration and, if requested, new Schedule II order forms (DEA Form-222, Official Order 

Form). A Renewal Application for Registration (DEA Form-224a) will only be sent to the 

registered address on file with DEA. It will not be forwarded. 

 

Termination of Registration 

Any practitioner desiring to discontinue business activities with respect to controlled 

substances must notify the nearest DEA field office (see Appendix E ) in writing. Along 

with the notification of termination of registration, the practitioner should send the DEA 

Certificate of Registration and any unused Official Order Forms (DEA Form-222) to the 

nearest DEA field office. 

Denial, Suspension or Revocation of Registration 

Under the CSA, DEA has the authority to deny, suspend, or revoke a DEA registration upon 

a finding that the registrant has: 

 1. Materially falsified any application filed 

 2. Been convicted of a felony relating to a controlled substance or a List I chemical 

 3. Had their state license or registration suspended, revoked, or denied 

 4. Committed an act which would render the DEA registration inconsistent with the 

 public interest 

5. Been excluded from participation in a Medicaid or Medicare program 

In determining the public interest, the CSA states the following factors are to be considered: 

1. The recommendation of the appropriate state licensing board or professional 

 disciplinary authority 

2. The applicant’s experience in dispensing or conducting research with respect to 

 controlled substances 

3. The applicant’s conviction record under federal or state laws relating to the 

 manufacture, distribution, or dispensing of controlled substances 

4. Compliance with applicable state, federal, or local laws relating to controlled 

 substances 

5. Such other conduct which may threaten the public health and safety 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 12 

Practitioner’s Use of a Hospital’s DEA Registration Number 

Practitioners (e.g., intern, resident, staff physician, mid-level practitioner) who are agents or

employees of a hospital or other institution may, when acting in the usual course of business 

or employment, administer, dispense, or prescribe controlled substances under the 

registration of the hospital or other institution in which they are employed, provided that: 

1. The dispensing, administering, or prescribing is in the usual course of 

professional practice 

2. Practitioners are authorized to do so by the state in which they practice 

3. The hospital or institution has verified that the practitioner is permitted to 

dispense, administer or prescribe controlled substances within the state 

4. The practitioner acts only within the scope of employment in the hospital or 

institution 

5. The hospital or institution authorizes the practitioner to dispense or prescribe 

under its registration and assigns a specific internal code number for each 

practitioner so authorized (See example of a specific internal code number 

below):

Hospital

DEA Registration

Number

Physician’s

Hospital Code

Number

AB1234567-012

A current list of internal codes and the corresponding individual practitioners is to be 

maintained by the hospital or other institution. This list is to be made available at all times to 

other registrants and law enforcement agencies upon request for the purpose of verifying the 

authority of the prescribing individual practitioner. 

Inappropriate Use of the DEA Registration Number 

DEA strongly opposes the use of a DEA registration number for any purpose other than the 

one for which it was intended, to provide certification of DEA registration in transactions 

involving controlled substances. The use of DEA registration numbers as an identification 

number is not an appropriate use and could lead to a weakening of the registration system. 

The Centers for Medicare and Medicaid Services has developed a National Provider 

Identification (NPI) number unique to each healthcare provider. The Final Rule for 

establishment of the NPI system was published in the Federal Register (FR 3434, Vol. 69, 

No. 15) by the Department of Health and Human Services on January 23, 2004. The 

effective date of this Final Rule was May 23, 2005; all covered entities must begin using the 

NPI in standard transactions by May 23, 2007. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 13 

Exemption of Federal Government Practitioners from 

Registration 

The requirement of registration is waived for any official of the U.S. Army, Navy, Marine 

Corps, Air Force, Coast Guard, Public Health Service, or Bureau of Prisons who is 

authorized to prescribe, dispense, or administer, but not to procure or purchase controlled 

substances in the course of his/her official duties. Such officials shall follow procedures set 

forth in Title 21, CFR § 1306 regarding prescriptions, but shall state the branch of service or 

agency (e.g., "U.S. Army" or "Public Health Service") and the service identification number 

of the issuing official in lieu of the registration number required on prescription forms. The 

service identification number for a Public Health Service employee is his/her Social Security 

identification number. 

If a Federal Government practitioners wish to maintain a DEA registration for a private 

practice, which would include prescribing for private patients, they must be fully licensed to 

handle controlled substances by the state in which they are located. Under these 

circumstances, the Federal Government practitioner will not be eligible for the fee exemption 

and must pay a fee for the registration. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 14 

SECTION III – SECURITY REQUIREMENTS 

Required Controls 

 

Title 21, CFR Section 1301.71(a), requires that all registrants provide effective controls and 

procedures to guard against theft and diversion of controlled substances. A list of factors is 

used to determine the adequacy of these security controls. Factors affecting practitioners 

include: 

 

1. The location of the premises and the relationship such location bears on security 

 needs 

2. The type of building and office construction 

3. The type and quantity of controlled substances stored on the premises 

4. The type of storage medium (safe, vault, or steel cabinet) 

5. The control of public access to the facility 

6. The adequacy of registrant’s monitoring system (alarms and detection 

 systems) 

7. The availability of local police protection 

 

Practitioners are required to store stocks of Schedule II through V controlled substances in a 

securely locked, substantially constructed cabinet. Practitioners authorized to possess 

carfentanil, etorphine hydrochloride and/or diprenorphine, must store these controlled 

substances in a safe or steel cabinet equivalent to a U.S. Government Class V security 

container. 

 

Registrants should not employ as an agent or employee who has access to controlled 

substances: 

 

1. Any person who has been convicted of a felony offense related to controlled 

 substances 

2. Any person who has been denied a DEA registration 

3. Any person who has had a DEA registration revoked 

4. Any person who has surrendered a DEA registration for cause 

 

Lastly, practitioners should notify the DEA, upon discovery, of any thefts or significant 

losses of controlled substances and complete a DEA Form 106 regarding such theft or loss. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 15 

Safeguards for Prescribers 

In addition to the required security controls, practitioners can utilize additional 

measures to ensure security. These include: 

1. Keep all prescription blanks in a safe place where they cannot be stolen; 

minimize the number of prescription pads in use. 

2. Write out the actual amount prescribed in addition to giving a number to 

discourage alterations of the prescription order. 

3. Use prescription blanks only for writing a prescription order and not 

 for notes. 

4. Never sign prescription blanks in advance. 

5. Assist the pharmacist when they telephone to verify information 

 about a prescription order; a corresponding responsibility rests with the 

 pharmacist who dispenses the prescription order to ensure the accuracy 

 of the prescription. 

6. Contact the nearest DEA field office (see Appendix E) to obtain or to 

 furnish information regarding suspicious prescription activities. 

7. Use tamper-resistant prescription pads. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 16 

SECTION IV – RECORDKEEPING 

REQUIREMENTS 

Recordkeeping Requirements 

Each practitioner must maintain inventories and records of controlled substances listed in 

Schedules I and II separately from all other records maintained by the registrant. Likewise, 

inventories and records of controlled substances in Schedules III, IV, and V must be 

maintained separately or in such a form that they are readily retrievable from the ordinary 

business records of the practitioner. All records related to controlled substances must be 

maintained and be available for inspection for a minimum of two years. 

A registered practitioner is required to keep records of controlled substances that are 

dispensed to the patient, other than by prescribing or administering, in the lawful course of 

professional practice. A registered practitioner is not required to keep records of controlled 

substances that are prescribed in the lawful course of professional practice, unless such 

substances are prescribed in the course of maintenance or detoxification treatment. A 

registered practitioner is not required to keep records of controlled substances that are 

administered in the lawful course of professional practice unless the practitioner regularly 

engages in the dispensing or administering of controlled substances and charges patients, 

either separately or together with charges for other professional services, for substances so 

dispensed or administered. A registered practitioner is also required to keep records of 

controlled substances administered in the course of maintenance or detoxification treatment 

of an individual. 

 

Inventory 

Each registrant who maintains an inventory of controlled substances must maintain a 

complete and accurate record of the controlled substances on hand and the date that 

the inventory was conducted. This record must be in written, typewritten, or printed 

form and be maintained at the registered location for at least two years from the date 

that the inventory was conducted. After an initial inventory is taken, the registrant 

shall take a new inventory of all controlled substances on hand at least every two 

years. 

Each inventory must contain the following information: 

1. Whether the inventory was taken at the beginning or close of business 

2. Names of controlled substances 

3. Each finished form of the substances (e.g., 100 milligram tablet) 

4. The number of dosage units of each finished form in the commercial container 

(e.g., 100 tablet bottle) 

5. The number of commercial containers of each finished form (e.g., four 100 

tablet bottles) 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 17 

6. Disposition of the controlled substances 

It is important to note that inventory requirements extend to controlled substance 

samples provided to practitioners by pharmaceutical companies. 

Disposal of Controlled Substances 

A practitioner may dispose of out-of-date, damaged, or otherwise unusable or 

unwanted controlled substances, including samples, by transferring them to a 

registrant who is authorized to receive such materials. These registrants are referred 

to as “Reverse Distributors.” The practitioner should contact the local DEA field 

office (See Appendix E) for a list of authorized Reverse Distributors. Schedule I and 

II controlled substances should be transferred via the DEA Form 222, while Schedule 

III–V compounds may be transferred via invoice. The practitioner should maintain 

copies of the records documenting the transfer and disposal of controlled substances 

for a period of two years. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 18 

SECTION V – VALID PRESCRIPTION 

REQUIREMENTS 

Prescription Requirements 

A prescription is an order for medication which is dispensed to or for an ultimate user. A 

prescription is not an order for medication which is dispensed for immediate administration 

to the ultimate user (for example, an order to dispense a drug to an inpatient for immediate 

administration in a hospital is not a prescription). 

A prescription for a controlled substance must be dated and signed on the date when issued.

The prescription must include the patient’s full name and address, and the practitioner’s full 

name, address, and DEA registration number. The prescription must also include: 

1. drug name 

2. strength 

3. dosage form 

4. quantity prescribed 

5. directions for use 

6. number of refills (if any) authorized 

A prescription for a controlled substance must be written in ink or indelible pencil or 

typewritten and must be manually signed by the practitioner on the date when issued. An 

individual (secretary or nurse) may be designated by the practitioner to prepare prescriptions 

for the practitioner’s signature. 

The practitioner is responsible for ensuring that the prescription conforms to all requirements 

of the law and regulations, both federal and state. 

 Who May Issue 

A prescription for a controlled substance may only be issued by a physician, dentist, 

podiatrist, veterinarian, mid-level practitioner, or other registered practitioner who is: 

1. Authorized to prescribe controlled substances by the jurisdiction in which the 

 practitioner is licensed to practice 

2. Registered with DEA or exempted from registration (that is, Public Health Service, 

 Federal Bureau of Prisons, or military practitioners) 

3. An agent or employee of a hospital or other institution acting in the 

 normal course of business or employment under the registration of the hospital or 

 other institution which is registered in lieu of the individual practitioner being 

 registered provided that additional requirements as set forth in the CFR are met. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 19 

 Purpose of Issue 

To be valid, a prescription for a controlled substance must be issued for a legitimate 

medical purpose by a practitioner acting in the usual course of professional practice. 

The practitioner is responsible for the proper prescribing and dispensing of controlled 

substances. In addition, a corresponding responsibility rests with the pharmacist who 

fills the prescription. An order purporting to be a prescription issued not in the usual 

course of professional treatment or in legitimate and authorized research is not a valid 

prescription within the meaning and intent of the Controlled Substances Act and the 

person knowingly filling such a purported prescription, as well as the person issuing it, 

shall be subject to the penalties provided for violations of the provisions of law relating 

to controlled substances. 

A prescription may not be issued in order for an individual practitioner to obtain 

controlled substances for supplying the individual practitioner for the purpose of 

general dispensing to patients. 

Schedule II Substances 

Schedule II controlled substances require a written prescription which must be signed by the 

practitioner. There is no federal time limit within which a Schedule II prescription must be 

filled after being signed by the practitioner. 

While some states and many insurance carriers limit the quantity of controlled substance 

dispensed to a 30-day supply, there are no specific federal limits to quantities of drugs 

dispensed via a prescription. For Schedule II controlled substances, an oral order is only 

permitted in an emergency situation. 

 Refills 

The refilling of a prescription for a controlled substance listed in Schedule II is 

prohibited (Title 21 U.S. Code § 829(a)). 

 

 Issuance of Multiple Prescriptions for Schedule II Substances 

DEA has revised its regulations regarding the issuance of multiple prescriptions for 

schedule II controlled substances. Under the new regulation, which became effective 

December 19, 2007, an individual practitioner may issue multiple prescriptions 

authorizing the patient to receive a total of up to a 90-day supply of a schedule II 

controlled substance provided the following conditions are met: 

1. Each separate prescription is issued for a legitimate medical purpose by an 

individual practitioner acting in the usual course of professional practice. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 20 

2. The individual practitioner provides written instructions on each prescription 

(other than the first prescription, if the prescribing practitioner intends for that 

prescription to be filled immediately) indicating the earliest date on which a 

pharmacy may fill each prescription. 

3. The individual practitioner concludes that providing the patient with multiple 

prescriptions in this manner does not create an undue risk of diversion or 

abuse. 

4. The issuance of multiple prescriptions is permissible under applicable state 

laws. 

5. The individual practitioner complies fully with all other applicable 

requirements under the Controlled Substances Act and Code of Federal 

Regulations, as well as any additional requirements under state law. 

It should be noted that the implementation of this change in the regulation should not be 

construed as encouraging individual practitioners to issue multiple prescriptions or to 

see their patients only once every 90 days when prescribing schedule II controlled 

substances. Rather, individual practitioners must determine on their own, based on 

sound medical judgment, and in accordance with established medical standards, 

whether it is appropriate to issue multiple prescriptions and how often to see their 

patients when doing so. 

Facsimile Prescriptions for Schedule II Controlled 

Substances 

In order to expedite the filling of a prescription, a prescriber may transmit a Schedule II 

prescription to the pharmacy by facsimile. The original Schedule II prescription must 

be presented to the pharmacist for review prior to the actual dispensing of the 

controlled substance. 

In an emergency, a practitioner may call-in a prescription for a Schedule II controlled 

substance by telephone to the pharmacy, and the pharmacist may dispense the 

prescription provided that the quantity prescribed and dispensed is limited to the 

amount adequate to treat the patient during the emergency period. The prescribing 

practitioner must provide a written and signed prescription to the pharmacist within 

seven days. Further, the pharmacist must notify DEA if the prescription is not received. 

 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 21 

Exceptions for Schedule II Facsimile Prescriptions

DEA has granted three exceptions to the facsimile prescription requirements for 

Schedule II controlled substances. The facsimile of a Schedule II prescription may 

serve as the original prescription as follows: 

 

 1. A practitioner prescribing Schedule II narcotic controlled substances to be 

compounded for the direct administration to a patient by parenteral, 

intravenous, intramuscular, subcutaneous or intraspinal infusion may transmit 

the prescription by facsimile. The pharmacy will consider the facsimile 

prescription a “written prescription” and no further prescription verification is 

required. All normal requirements of a legal prescription must be followed. 

2. Practitioners prescribing Schedule II controlled substances for residents of 

Long Term Care Facilities (LTCF) may transmit a prescription by facsimile to 

the dispensing pharmacy. The practitioner’s agent may also transmit the 

prescription to the pharmacy. The facsimile prescription serves as the original 

written prescription for the pharmacy. 

3. A practitioner prescribing a Schedule II narcotic controlled substance for a 

patient enrolled in a hospice care program certified and/or paid for by 

Medicare under Title XVIII or a hospice program which is licensed by the 

state may transmit a prescription to the dispensing pharmacy by facsimile. 

The practitioner or the practitioner’s agent may transmit the prescription to the 

pharmacy. The practitioner or agent will note on the prescription that it is for 

a hospice patient. The facsimile serves as the original written prescription. 

Schedule III-V Substances 

A prescription for controlled substances in Schedules III, IV, and V issued by a practitioner, 

may be communicated either orally, in writing, or by facsimile to the pharmacist, and may be 

refilled if so authorized on the prescription or by call-in. 

 Refills 

Schedule III and IV controlled substances may be refilled if authorized on the 

prescription. However, the prescription may only be refilled up to five times within six 

months after the date on which the prescription was issued. After five refills or after six 

months, whichever occurs first, a new prescription is required. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 22 

Facsimile Prescriptions for Schedule III-V Substances 

Prescriptions for Schedules III-V controlled substances may be transmitted by facsimile 

from the practitioner or an employee or agent of the individual practitioner to the 

dispensing pharmacy. The facsimile is considered to be equivalent to an original 

prescription. 

 Telephone Authorization for Schedule III-V Prescriptions 

 A pharmacist may dispense a controlled substance listed in Schedule III, IV, or V 

pursuant to an oral prescription made by an individual practitioner and promptly 

reduced to writing by the pharmacist containing all information required for a valid 

prescription, except for the signature of the practitioner. 

Delivery of a Controlled Substance to Persons Outside the U.S. 

Controlled substances that are dispensed pursuant to a legitimate prescription may not be 

delivered or shipped to individuals in another country. Any such delivery or shipment is a 

prohibited export under the CSA. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 23 

SECTION VI – OPIOID (NARCOTIC) 

ADDICTION TREATMENT PROGRAMS 

The Narcotic Addiction Treatment Act of 1974 and the Drug Addiction Treatment Act of 

2000 amended the CSA with respect to the use of controlled substances in the medical 

treatment of addiction. These laws established the procedures for approval and licensing of 

practitioners involved in the treatment of opioid addiction as well as improving the quality 

and delivery of that treatment to the segment of society in need. 

Practitioners wishing to administer and dispense approved Schedule II controlled substances 

(that is, methadone) for maintenance and detoxification treatment must obtain a separate 

DEA registration as a Narcotic Treatment Program. Application for registration as a 

Narcotic Treatment Program is made using DEA Form 363. In addition to obtaining this 

separate DEA registration, this type of activity also requires the approval and registration of 

the Center for Substance Abuse Treatment (CSAT) within the Substance Abuse and Mental 

Health Services Administration (SAMHSA) of the Department of Health and Human 

Services (HHS), as well as the applicable state methadone authority. 

If a practitioner wishes to prescribe, administer, or dispense Schedule III, IV, or V controlled 

substances approved for addiction treatment (i.e., buprenorphine drug products), the 

practitioner must request a waiver (Form SMA-167) and fulfill the requirements of CSAT. 

CSAT will then notify DEA of all waiver requests. DEA will review each request. If DEA 

approves this waiver, the practitioner will receive a Unique Identification Number. If a 

practitioner chooses to dispense controlled substances, the practitioner must maintain, 

separate from all other records, for a period of at least two years, all required records of 

receipt, storage, and distribution. If a practitioner chooses to prescribe these controlled 

substances, the practitioner must utilize their Unique Identification Number on the 

prescription in addition to his/her regular DEA registration number. The practitioner must 

also maintain a record of each such prescription for a period of at least two years. 

Practitioners should be aware that there may be limits on how many patients they may treat 

for opioid addiction at any given time and should check with SAMHSA to determine these 

limits. 

Note that not all treatment programs utilize controlled substances, that is, some are drug free. 

Accordingly, these activities do not require DEA registration or approval. 

Practitioners can find additional information regarding addiction treatment by visiting DEA’s 

Office of Diversion Control website at www.DEAdiversion.usdoj.gov. Click on 

“Publications,” then “Narcotic Treatment Programs: Best Practices Guidelines.” The DEA 

application Form 363 may be completed on-line. 

To learn more about CSAT’s requirements, practitioners may visit one or more of the 

following websites: www.samhsa.gov/centers/csat2002/csat_frame.html, 

www.csat.samhsa.gov, or www.buprenorphine.samhsa.gov. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 24 

If the practitioner has a patient who is in need of addiction treatment, but does not wish to 

treat the individual, the practitioner can refer the patient to an existing facility through the 

following website: www.findtreatment.samhsa.gov.
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 25 

APPENDICES 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 26 

APPENDIX A 

CSA & CFR Definitions 

Administer 

The direct application of a controlled substance to the body of a patient or research 

subject by 1) a practitioner or (in his presence) by his authorized agent, or 2) the 

patient or research subject at the direction and in the presence of the practitioner, 

whether such application is by injection, inhalation, ingestion, or any other means. 

Dispense 

To deliver a controlled substance to an ultimate user or research subject by, or 

pursuant to the lawful order of, a practitioner, including the prescribing and 

administering of a controlled substance and the packaging, labeling, or 

compounding necessary to prepare the substance for such delivery. 

Dispenser 

An individual practitioner, institutional practitioner, pharmacy or, pharmacist who 

dispenses a controlled substance. 

Individual Practitioner 

A physician, dentist, veterinarian, or other individual licensed, registered or 

otherwise permitted, by the United States or the jurisdiction in which they practice, 

to dispense a controlled substance in the course of professional practice, but does 

not include a pharmacist, a pharmacy, or an institutional practitioner. 

Institutional Practitioner 

A hospital or other person (other than an individual) licensed, registered or otherwise 

permitted, by the United States or the jurisdiction in which it practices, to dispense a 

controlled substance in the course of professional practice, but does not include a 

pharmacy. 

Inventory 

All factory and branch stocks in finished form of a basic class of controlled 

substance manufactured or otherwise acquired by a registrant, whether in bulk, 

commercial containers, or contained in pharmaceutical preparations in the 

possession of the registrant (including stocks held by the registrant under separate 

registration as a manufacturer, importer, exporter, or distributor). 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 27 

Long Term Care Facility 

A nursing home, retirement care, mental care, or other facility or institution which 

provides extended health care to resident patients. 

Mid-level Practitioner 

An individual practitioner, other than a physician, dentist, veterinarian, or podiatrist, 

who is licensed, registered or otherwise permitted by the United States or the 

jurisdiction in which he/she practices, to dispense a controlled substance in the 

course of professional practice. Examples of mid-level practitioners include, but 

are not limited to, health care providers such as nurse practitioners, nurse midwives, 

nurse anesthetists, clinical nurse specialists, and physician assistants who are 

authorized to dispense controlled substances by the state in which they practice. 

Pharmacist 

Any pharmacist licensed by a state to dispense controlled substances, and shall 

include any other person (e.g., pharmacist intern) authorized by a state to dispense 

controlled substances under the supervision of a pharmacist licensed by such state. 

Prescription 

An order for medication which is dispensed to or for an ultimate user but does not 

include an order for medication which is dispensed for immediate administration to 

the ultimate user (e.g., an order to dispense a drug to a bed patient for immediate 

administration in a hospital is not a prescription). 

Readily Retrievable 

Certain records are kept by automatic data processing systems or other electronic or 

mechanized record keeping systems in such a manner that they can be separated out 

from all other records in a reasonable time and/or records are kept on which certain 

items are asterisked, redlined, or in some other manner visually identifiable apart 

from other items appearing on the records. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 28 

APPENDIX B 

Questions and Answers

The following questions are those that are frequently encountered by DEA’s Office of 

Diversion Control and its field units. These questions and their accompanying answers 

are provided in context of the CSA and its federal regulations. 

Q Are separate registrations required for separate locations? 

 A separate registration is required for each principal place of business or 

professional practice where controlled substances are stored or dispensed by a 

person. 

Q Does a practitioner need a separate registration to treat patients at remote 

health care facilities? 

A Separate registration is not required in an office used by a practitioner (who is 

registered at another location) where controlled substances are prescribed but 

neither administered nor otherwise dispensed as a regular part of the professional 

practice of the practitioner at such office, and where no supplies of controlled 

substances are maintained. 

Q Do all practitioners in a group practice need to be registered? 

A An individual practitioner who is an agent or employee of another practitioner 

(other than a mid-level practitioner) registered to dispense controlled substances 

may, when acting in the normal course of business or employment, administer or 

dispense (other than by issuance of prescription) controlled substances if and to the 

extent that such individual practitioner is authorized or permitted to do so by the 

jurisdiction in which he or she practices, under the registration of the employer or 

principal practitioner in lieu of being registered him/herself. 

Q Do medical residents assigned to hospitals need to register? 

A An individual practitioner who is an agent or employee of a hospital or other 

institution may, when acting in the normal course of business or employment, 

administer, dispense, or prescribe controlled substances under the registration of the 

hospital or other institution which is registered in lieu of being registered provided 

that additional requirements as set forth in the CFR are met. 

A
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 29 

Q Are military personnel exempted from registration? 

A Registration is waived for any official of the U.S. Army, Navy, Marine Corps, 

Air Force, or Coast Guard who is authorized to prescribe, dispense, or administer, 

but not procure or purchase, controlled substances in the course of his/her official 

duties. Such officials must follow procedures set forth in 21 CFR Part 1306 

regarding prescriptions. Branch of service or agency and the service identification 

number of the issuing official is required on the prescription form in lieu of the 

DEA registration number. 

If any exempted official engages as a private individual in any activity or group of 

activities for which registration is required, that individual must obtain a registration 

for those private activities. 

Further, practitioners serving in the U.S. Military are exempt from registering with 

DEA, but are not authorized to procure or purchase controlled substances in the 

course of their official duties. 

A number of states also require military practitioners to acquire a separate state 

license if they issue prescriptions that are filled outside the military facility where 

they practice. 

Q Are contract practitioners working at U.S. Military Installations also exempt 

from registration? 

A They are not exempt. A contract practitioner who is not an official of the 

military on active duty, but is engaged in medical practice at a military installation, 

must possess a current DEA registration. The individual must also possess a valid 

state license for the same state in which he/she is registered with DEA. 

Q What should a practitioner do if he/she discovers a theft or loss? 

A Registrants must notify the DEA field office in their area of the theft or 

significant loss of any controlled substances upon discovery. The registrant must 

also complete DEA Form 106 documenting the loss or theft. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 30 

Q What is meant by “acceptable medical practice?” 

A The legal standard that a controlled substance may only be prescribed, administered, 

or dispensed for a legitimate medical purpose by a physician acting in the usual course of 

professional practice has been construed to mean that the prescription must be “in 

accordance with a standard of medical practice generally recognized and accepted in the 

United States.” 

Federal courts have long recognized that it is not possible to expand on the phrase 

“legitimate medical purpose in the usual course of professional practice” in a way that 

will provide definitive guidelines to address all the varied situations physicians may 

encounter. 

While there are no criteria to address every conceivable instance of prescribing, there are 

recurring patterns that may be indicative of inappropriate prescribing: 

• An inordinately large quantity of controlled substances prescribed or large 

numbers of prescriptions issued compared to other physicians in an area; 

• No physical examination was given; 

• Warnings to the patient to fill prescriptions at different drug stores; 

• Issuing prescriptions knowing that the patient was delivering the drugs to 

others; 

• Issuing prescriptions in exchange for sexual favors or for money; 

• Prescribing of controlled drugs at intervals inconsistent with legitimate 

medical treatment; 

• The use of street slang rather than medical terminology for the drugs 

prescribed; or 

• Νo logical relationship between the drugs prescribed and treatment of the 

condition allegedly existing. 

Each case must be evaluated based on its own merits in view of the totality of 

circumstances particular to the physician and patient. 

For example, what constitutes “an inordinately large quantity of controlled substances,” 

can vary greatly from patient to patient. A particular quantity of a powerful Schedule II 

opioid might be blatantly excessive for the treatment of a particular patient's mild 

temporary pain, yet insufficient to treat the severe unremitting pain of a cancer patient. 

Q What information is required to be provided on a written prescription? 

A All written prescriptions for controlled substances must be dated as of, and 

signed on, the date when issued. Each prescription must indicate the full name and 

address of the patient, the drug name, strength, dosage form, quantity prescribed, 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 31 

directions for use and the name, address, and DEA number of the practitioner. 

Further, prescriptions must be written in ink, indelible pencil, or by typewriter, and 

must be manually signed by the practitioner. 

Q What is meant by “date of issuance?” 

A The date a prescription is issued is the same date that the prescribing practitioner 

actually writes and signs the prescription.

Q Is there a time limit for filling Schedule II prescriptions? 

A There is no federal time limit for filling Schedule II prescriptions. However, 

some state laws do set time limits. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 32 

APPENDIX C 

Summary of Controlled Substances Act Requirements

Schedule II Schedule III & IV Schedule V 

Registration Required Required Required 

Receiving 

Records 

Order Forms 

(DEA Form-222) 

Invoices, 

Readily Retrievable 

Invoices, 

Readily Retrievable 

Prescriptions Written Prescription 

(See exceptions*) 

Written, Oral, or Fax Written, Oral, Fax, or 

Over The Counter** 

Refills No No more than 5 within 6 

months 

As authorized when 

prescription is issued 

Distribution 

Between 

Registrants 

Order Forms 

(DEA Form-222) 

Invoices Invoices 

Security Locked Cabinet or 

Other Secure Storage 

Locked Cabinet or 

Other Secure Storage 

Locked Cabinet or 

Other Secure Storage 

Theft or 

Significant Loss 

Report and complete 

DEA Form 106 

Report and complete 

DEA Form 106 

Report and complete 

DEA Form 106 

Note: All records must be maintained for 2 years, unless a state requires a longer period. 

* Emergency prescriptions require a signed follow-up prescription. 

 Exceptions: A facsimile prescription serves as the original prescription when issued to residents 

 of Long Term Care Facilities, Hospice patients, or compounded IV narcotic medications.

** Where authorized by state controlled substances authority. 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 33 

APPENDIX D 

Internet Resources 

DEA’s Diversion Control Program Website

 www.DEAdiversion.usdoj.gov 

DEA Homepage

 www.dea.gov 

U.S. Government Printing Office 

 www.gpoaccess.gov/cfr/index.html

Provides access to the Code of Federal Regulations (21 CFR, Parts 1300 to end), 

primary source for the Practitioner’s Manual, and the Federal Register which 

contains proposed and finalized amendments to the CFR. 

Office of National Drug Control Policy (ONDCP)

 www.whitehousedrugpolicy.gov

Food and Drug Administration

 www.FDA.gov 

HHS & SAMHSA’s National Clearinghouse for Alcohol and Drug 

Information

 www.health.org 

SAMHSA/CSAT

 www.csat.samhsa.gov

Federation of State Medical Boards

www.FSMB.org 

National Association of Boards of Pharmacy

 www.nabp.net 

National Association of State Controlled Substances Authorities

 www.nascsa.org
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 34 

APPENDIX E 

Drug Enforcement Administration 

Diversion Field Office Locations 

For address and telephone number updates, please see the DEA website: 

www.deadiversion.usdoj.gov

NORTHERN ALABAMA 

DEA Birmingham Resident Office 

920 Eighteenth Street, North 

Birmingham, Alabama 35203 

(205) 321-1300 

SOUTHERN ALABAMA 

DEA Mobile Resident Office 

900 Western America Circle 

Suite 501 

Mobile, Alabama 36609 

(334) 441-5831 

ALASKA 

DEA Seattle Field Division 

 400 2nd Avenue West 

 Seattle, Washington 98119 

 (206) 553-5443 

NORTHERN & CENTRAL 

ARIZONA 

DEA Phoenix Field Division 

 3010 N. 2nd Street, Suite 301 

 Phoenix, Arizona 85012 

 (602) 664-5600 

SOUTHERN ARIZONA 

DEA Tucson District Office 

 3285 E. Hemisphere Loop 

 Tucson, Arizona 85706 

 (520) 573-5500 

ARKANSAS 

DEA Little Rock Resident Office 

 10825 Financial Center Pkwy, Suite 200 

 Little Rock, Arkansas 72211 

 (501) 312-8602 

CENTRAL & COASTAL 

CALIFORNIA 

DEA San Francisco Field Division 

 450 Golden Gate Avenue, 14th Floor 

 San Francisco, California 94102 

 (415) 436-7900 

DEA San Jose Resident Office 

 One North First Street, Suite 405 

 San Jose, California 95113 

 (408) 291-7235 

CENTRAL CALIFORNIA 

DEA Fresno Resident Office 

 2444 Main Street, Suite 240 

 Fresno, California 93721 

 (559)487-5402 

NORTHERN CALIFORNIA 

DEA Oakland Resident Office 

 1301 Clay Street, Suite 460N 

 PO Box 70301 

 Oakland, California 94612 

 (510) 637-5600 

 DEA Sacramento District Office 

 4328 Watt Avenue 

 Sacramento, California 95821 

 (916) 566-7401 

SOUTH CENTRAL CALIFORNIA 

DEA Los Angeles Field Division 

 255 East Temple Street, 20th Floor 

 Los Angeles, California 90012 

 (213) 621-6700 

DEA Riverside District Office 

 4470 Olivewood Avenue 

 Riverside, California 92501- 4155 

 (909) 328-6000 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 35 

SOUTHERN CALIFORNIA 

DEA San Diego Field Division 

 4560 Viewridge Avenue 

 San Diego, California 92123 

 (858) 616-4100 

COLORADO 

DEA Denver Field Division 

 115 Inverness Drive, East 

 Englewood, Colorado 80112 

 (303) 705-7300 

SOUTHERN COLORADO 

DEA Colorado Springs Resident Office 

 Plaza of the Rockies 

 111 S Tejon, Suite 306 

 Colorado Springs, Colorado 80903 

 (719) 866-6100 

CONNECTICUT 

DEA Hartford Resident Office 

 450 Main Street, Room 628 

 Hartford, Connecticut 06103 

 (860) 240-3700 

DELAWARE 

DEA Philadelphia Field Division 

 William J. Green Federal Building 

 600 Arch Street, Room 10224 

 Philadelphia, Pennsylvania 19106 

 (215) 597-9540 

DISTRICT OF COLUMBIA 

DEA Washington Field Division 

 TechWorld Plaza 

 801 I Street, NW, Suite 500 

 Washington, DC 20001 

 (202) 305-8500 

NORTHERN FLORIDA 

DEA Tallahassee Resident Office 

 3384 Capital Circle, NE 

 Tallahassee, Florida 32308 

 (850) 942-8417 

CENTRAL FLORIDA 

DEA Orlando Resident Office 

 Heathrow Business Center 

 300 International Pkwy, Suite 424 

 Heathrow, Florida 32746 

 (407) 333-7046 

WEST CENTRAL FLORIDA 

DEA Tampa District Office 

 4950 W. Kennedy Boulevard, Suite 400 

 Tampa, Florida 33609 

 (813) 287-5165 

SOUTHEASTERN FLORIDA 

DEA Miami Field Division 

 8400 NW 53rd Street 

 Miami, Florida 33166 

 (305) 994-4870 

GEORGIA 

DEA Atlanta Field Division 

 75 Spring Street, SW, Suite 800 

 Atlanta, Georgia 30303 

 (404) 893-7000 

EASTERN GEORGIA 

DEA Savannah Resident Office 

 56 Park of Commerce Boulevard 

 Savannah, Georgia 31405 

 (912) 447-1035 

HAWAII 

DEA Honolulu District Office 

 300 Ala Moana Boulevard, Room 3-147 

 Honolulu, Hawaii 96850 

 (808) 541-1930 

NORTHERN IDAHO 

DEA Seattle Field Division 

 400 2nd Avenue West 

 Seattle, Washington 98119 

 (206) 553-5443 

SOUTHERN IDAHO 

DEA Boise Resident Office 

 607 North 8th Street, Suite 400 

 Boise, Idaho 83702-5518 

 (208) 334-1620 

NORTHERN & CENTRAL 

ILLINOIS 

 DEA Chicago Field Division 

 Klyuczynski Federal Building 

 230 South Dearborn Street, Suite 1200 

 Chicago, Illinois 60604 

 (312) 353-7875 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 36 

CENTRAL ILLINOIS 

DEA Springfield Resident Office 

 2875 Via Verde Street 

 Springfield, Illinois 62703 

 (217) 585-2750 

SOUTHERN ILLINOIS 

DEA St. Louis Field Division 

 317 South 16th Street 

 St. Louis, Missouri 63103 

 (314) 538-4600 

INDIANA 

DEA Indianapolis District Office 

 575 N Pennsylvania Street, Room 408 

 Indianapolis, Indiana 46204 

 (317) 226-7977 

 

NORTHERN INDIANA 

DEA Merrillville Resident Office 

 1571 East 85th Avenue, Suite 200 

 Merrillville, Indiana 46410 

 (219) 681-7000 

IOWA 

DEA Des Moines Resident Office 

 210 Walnut Street, Room 937 

 Des Moines, Iowa 50309 

 (515) 284-4709 

KANSAS 

DEA Kansas City Resident Office 

 8600 Farley, Suite 200 

 Overland Park, Kansas 66212 

 (913) 825-4116 

KENTUCKY 

DEA Louisville Resident Office 

 600 Dr. Martin Luther King Jr. Place 

 Suite 1006 

 Louisville, Kentucky 40202 

 (502) 582-5908 

SOUTHEASTERN KENTUCKY 

DEA London Resident Office 

 PO Box 5065 

 London, Kentucky 40745 

 (606) 862-4500 

LOUISIANA 

DEA New Orleans Field Division 

 3838 N Causeway Boulevard, Suite 1800 

 Lakeway III 

 Metairie, Louisiana 70002 

 (504) 840-1100 

MAINE 

DEA Boston Field Division 

 JFK Federal Building 

 15 New Sudbury Street, Room E-400 

 Boston, Massachusetts 02203-0402 

 (617) 557-2100 

MARYLAND 

DEA Baltimore District Office 

 200 St. Paul Place, Suite 2222 

 Baltimore, Maryland 21202-2004 

 (410) 244-3500 

MASSACHUSETTS 

DEA Boston Field Division 

 JFK Federal Building 

 15 New Sudbury Street, Room E-400 

 Boston, Massachusetts 02203-0131 

 (617) 557-2100 

MICHIGAN 

DEA Detroit Field Division 

 431 Howard Street 

 Detroit, Michigan 48226 

 (313) 234-4000 

MINNESOTA 

DEA Minneapolis/St Paul Resident 

Office 

 330 Second Avenue S, Suite 450 

 Minneapolis, Minnesota 55401 

 (612) 725-3280 

MISSISSIPPI 

DEA Jackson District Office 

 100 W. Capitol Street, Suite 1213 

 Jackson, Mississippi 39269 

 (601) 965-4400 

EASTERN MISSOURI 

DEA St Louis Field Division 

 317 South 16th Street 

 St. Louis, Missouri 63103 

 (314) 538-4600 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 37 

WESTERN MISSOURI 

DEA Kansas City Resident Office 

 8600 Farley, Suite 200 

 Overland Park, Kansas 66212 

 (913) 825-4118 

MONTANA 

DEA Denver Field Division 

 115 Inverness Drive, East 

 Englewood, Colorado 80112 

 (303) 705-7300 

NEBRASKA 

DEA Des Moines Resident Office 

 210 Walnut Street, Room 509 

 Des Moines, Iowa 50309 

 (515) 284-4709 

NEVADA 

DEA Las Vegas District Office 

 550 South Main, Suite A 

 Las Vegas, Nevada 89101 

 (702) 759-8016 

NEW HAMPSHIRE 

DEA Boston Field Division 

 JFK Federal Building 

 15 New Sudbury Street, Room E-400 

 Boston, Massachusetts 02203-0402 

 (617) 557-2100 

NORTHERN & CENTRAL 

NEW JERSEY 

DEA Newark Field Division 

 80 Mulberry Street, 2nd Floor 

 Newark, New Jersey 07102 

 (973) 776-1100 

SOUTHERN NEW JERSEY 

DEA Camden Resident Office 

 211 Boulevard Avenue 

 Maple Shade, New Jersey 08052 

 (856) 321-2439 

NEW MEXICO 

DEA Albuquerque District Office 

 301 Martin Luther King Ave, NE 

 Albuquerque, New Mexico 87102 

 (505) 346-7419 

NEW YORK 

DEA New York Field Division 

 99 Tenth Avenue 

 New York, New York 10011 

 (212) 337-3900 

CENTRAL & WESTERN 

NEW YORK 

DEA Buffalo Resident Office 

 28 Church Street, Suite 300 

 Buffalo, New York 14202 

 (716) 551-3391 

LONG ISLAND NEW YORK 

DEA Long Island District Office 

 175 Pinelawn Road, Suite 205 

 Melville, New York 11747 

 (631) 420-4500 

NORTH CAROLINA 

DEA Greensboro Resident Office 

 1801 Stanley Road, Suite 201 

 Greensboro, North Carolina 27407 

 (336) 547-4219 

NORTH DAKOTA 

DEA Minneapolis/St Paul Resident 

Office 

 330 Second Avenue S, Suite 450 

 Minneapolis, Minnesota 55401 

 (612) 725-3280 

NORTHERN OHIO 

DEA Cleveland Resident Office 

 Courthouse Square 

 310 Lakeside Avenue, Suite 395 

 Cleveland, Ohio 44113 

 (216) 552-3705 

SOUTHERN & CENTRAL OHIO 

DEA Columbus Resident Office 

 500 S Front Street, Suite 612 

 Columbus, Ohio 43215 

 (614) 255-4145 

SOUTHERN OHIO 

DEA Cincinnati Resident Office 

 36 East 7th Street, Suite 1900 

 Cincinnati, Ohio 45202 

 (513) 684-3671 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 38 

NORTHEASTERN OKLAHOMA 

DEA Tulsa Resident Office 

 Three Memorial Place 

 7615 E 63rd Place, Suite 250 

 Tulsa, Oklahoma 74133 

 (918) 459-9600 

OKLAHOMA 

DEA Oklahoma City District Office 

 9900 Broadway Extension 

 Oklahoma City, Oklahoma 73114 

 (405) 475-7500 

OREGON 

 DEA Portland District Office 

 1220 SW 3rd Avenue, Suite 1525 

 Portland, Oregon 97204 

 (503) 326-5739 

EASTERN PENNSYLVANIA 

 DEA Philadelphia Field Division 

 William J. Green Federal Building 

 600 Arch Street, Room 10224 

 Philadelphia, Pennsylvania 19106 

 (215) 861-3474 

WESTERN PENNSYLVANIA 

 DEA Pittsburgh Resident Office 

 Federal Building 

 1000 Liberty Avenue, Room 1328 

 Pittsburg, Pennsylvania 15222 

 (412) 395-4502 

PUERTO RICO 

 DEA Caribbean Field Division 

 Metro Office Park, #17, calle 2 

 San Juan, Puerto Rico 00968-1706 

 (787) 775-1815 

RHODE ISLAND 

 DEA Boston Field Division 

 JFK Federal Building 

 15 New Sudbury Street, Room E-400 

 Boston, Massachusetts 02203-0402 

 (617) 557-2100 

SOUTH CAROLINA 

 DEA Columbia District Office 

 1835 Assembly Street, Suite 1229 

 Columbia, South Carolina 29201 

 (803) 253-3441 

SOUTH DAKOTA 

 DEA Des Moines Resident Office 

 210 Walnut Street, Room 509 

 Des Moines, Iowa 50309 

 (515) 284-4793 

TENNESSEE 

 DEA Nashville District Office 

 801 Broadway, Suite 500 

 Nashville, Tennessee 37203 

 (615) 736-2559 

NORTHERN TEXAS 

 DEA Dallas Field Division 

 10160 Technology Boulevard 

 Dallas, Texas 75220 

 (214) 366-6900 

TEXAS 

 DEA Fort Worth Resident Office 

 819 Taylor Street, Room 13A33 

 Ft Worth, Texas 76102 

 (817) 978-3455 

EASTERN & SOUTHERN TEXAS 

 DEA Houston Field Division 

 1433 west Loop S, Suite 600 

 Houston, Texas 77027-9506 

 (713) 693-3000 

CENTRAL & WESTERN TEXAS 

 DEA San Antonio District Office 

 10127 Morocco, Suite 200 

 San Antonio, Texas 78216 

 (210) 442-5634

CENTRAL TEXAS 

 DEA Waco Post of Duty 

 6801 Sanger Avenue, Suite 2000 

 Waco, Texas 76710 

 (254) 741-1920 

WESTERN TEXAS 

 DEA El Paso Field Division 

 El Paso Federal Justice Center 

 660 S Mesa Hills Drive, Suite 2000 

 El Paso, Texas 79912 

 (915) 832-6000 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 39 

UTAH 

 DEA Salt Lake City Resident Office 

 348 East South Temple 

 Salt Lake City, Utah 84111 

 (801) 524-4156 

VERMONT 

 DEA Hartford Resident Office 

 450 Main Street, Room 628 

 Hartford, Connecticut 06103 

 (860) 240-3700 

VIRGIN ISLANDS 

 DEA Caribbean Field Division 

 Metro Office Park, #17, calle 2 

 San Juan, Puerto Rico 00968-1706 

 (787) 775-1815 

VIRGINIA 

 DEA Richmond Resident Office 

 111 Greencourt Road 

 Richmond, Virginia 23228 

 (804) 627-6307 

WASHINGTON STATE 

 DEA Seattle Field Division 

 400 2nd Avenue, West 

 Seattle, Washington 98119 

 (206) 553-1147 

WEST VIRGINIA 

 DEA Charleston Resident Office

 2 Monongalia Street, Suite 202 

 Charleston, West Virginia 25302 

 (304) 347-5209 

WISCONSIN 

 DEA Milwaukee District Office 

 1000 N. Water Street, Suite 1010 

 Milwaukee, Wisconsin 53202 

 (414) 297-3395 

WYOMING 

 DEA Salt Lake City Resident Office 

 348 East South Temple 

 Salt Lake City, Utah 84111 

 (801) 524-4156 

HEADQUARTERS 

 Office of Diversion Control 

 Registration Unit / ODRR 

 Washington, DC 20537 

 (202) 307-7250 

 (800) 882-9539 

NOTE: 

The address in Atlanta, Georgia is listed on the 

application and renewal application for mailing 

applications ONLY. It is a Financial Institution and 

not the physical address of the DEA. All inquiries 

relating to DEA registrations must be directed to the 

following: 

Telephone inquiries: 1-800-882-9539 or 

Written inquiries: Drug Enforcement Administration 

 Registration Unit – ODRR 

 Washington, DC 20537 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 40 

APPENDIX F 

Small Business and Agriculture 

Regulatory Enforcement Ombudsman

The Small Business and Agriculture Regulatory Enforcement Ombudsman and 10 

Regional Fairness Boards were established to receive comments from small 

businesses about federal agency enforcement actions. The Ombudsman will 

annually evaluate the enforcement activities and rate each agency’s responsiveness 

to small business. If you wish to comment on DEA enforcement actions, you may 

contact the Ombudsman at 1-888-REG-FAIR (1-888-734-3247). 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 41 

APPENDIX G

Additional Assistance

This publication is intended to provide guidance and information on the requirements 

of the Controlled Substances Act and its implementing regulations. If you require 

additional clarification or assistance, or wish to comment on any matter regarding the 

DEA’s requirements or regulatory activities, please contact your local DEA Diversion 

field office (see Appendix E). Every effort will be made to respond promptly to your 

inquiry. 

Plain Language

The Drug Enforcement Administration has made every effort to write this manual in 

clear, plain language. If you have suggestions as to how to improve the clarity of this 

manual, please contact us at: 

Drug Enforcement Administration 

Office of Diversion Control 

Liaison and Policy Section 

Washington, D.C. 20537 

Telephone: (202) 307-7297 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 42 

APPENDIX H – DEA FORMS 

The following pages provide samples of several forms frequently encountered by DEA 

registrants. Included are: 

DEA Form 41 Registrants Inventory of Drugs Surrendered 

DEA Form 106 Report of Theft or Loss of Controlled Substances 

DEA Form 222 U.S. Official Order Form for Controlled Substances 

DEA Form 224 Application for Registration 

DEA Form 224a Renewal Application for DEA Registration 

DEA Form 363 Application for Registration as a Narcotic Treatment Program 

DEA Form 363a Renewal Application for DEA Registration as a Narcotic 

 Treatment Program 

 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 43 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 44 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 45 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 46 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 47 

See Reverse of PURCHASER’S

Copy of Instructions

No order form may be issued for Schedule I and II substances unless a

completed application form has been received, (21 CFR 1305.04).

OMB APPROVAL

No. 1117-0010

TO: (Name of Supplier) STREET ADDRESS

CITY and STATE DATE TO BE FILLED IN BY SUPPLIER

SUPPLIERS DEA REGISTRATION No.

L TO BE FILLED IN BY PURCHASER

I

N

E

No.

No. of

Packages

Size of

Package Name of Item National Drug Code Packages

Shipped

Date

Shipped

1

2

3

4

5

6

7

8

9

10

LAST LINE

COMPLETED (MUST BE 10 OR LESS)

SIGNATURE OR PURCHASER

OR ATTORNEY OR AGENT

Date Issued DEA Registration No.

Schedules

Registered as a No. of this Order Form

Name and Address of Registrant

DEA Form-222

(Oct. 1992)

U.S. OFFICIAL ORDER FORMS - SCHEDULES I & II

DRUG ENFORCEMENT ADMINISTRATION

SUPPLIER’S Copy 1

DEPICTION of PAGE 1 of DEA FORM-222

U.S. OFFICIAL ORDER FORM - SCHEDULES I & II

Note: The graphic illustrated above is not intended to be used as an actual 

order form.
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 48 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 49 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 50 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 51 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 52 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 53 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 54 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 55 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 56 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 57 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 58 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 59 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 60 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 61 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 62 
Drug Enforcement Administration 

Practitioner’s Manual ------------------------------------------------------------------------------------------------------------ 

2006 Edition 

Page 63